Clinical trial · Interventional
Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford
Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford - A Pilot Study
NCT05416554CI-TRIAL-00115763withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): No participants enrolled
Summary
Brief summary (as posted)
This study aims to assess the feasibility of performing neuropsychological testing to measure the cognitive performance of individuals following Axicabtagene ciloleucel CAR-T therapy at Stanford.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Neuropsychological testing | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Neuropsychological testing
- description
- Participants will take neuropsychological testing in-person or via telehealth video
- interventionNames
- Behavioral: Neuropsychological testing
Primary outcomes (2)
- measure
- Number of patients who complete neuropsychological testing in the post-CAR-T adult population
- timeFrame
- 6 months
- measure
- Number of patients who complete telehealth neuropsychological testing in the post-CAR-T adult
- timeFrame
- 6 months
Secondary outcomes (9)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * \>/= 18 years-old * Treated with Axicabtagene ciloleucel CAR-T therapy at Stanford Or * Treated with standard commercial Axicabtagene ciloleucel CAR-T therapy elsewhere and followed primarily by SHC Blood and Bone Marrow transplant providers * \>/= 6 months from the date of CAR-T infusion * Fluent in English * Able to attend and participate in in-person testing (Arm I) * Able to participate in remote video testing with adequate workspace, computer and internet capabilities for a reliable telehealth video connection (Arm II) Exclusion Criteria: * Concurrent enrollment in a CAR-T therapeutics research study * Unable to be present for the scheduled testing * Unable to participate in testing due to severe cognitive or physical limitation * Actively receiving chemotherapy * Progressive cancer
References
Publications (0)
Data not yet available
No reference posted for this study.